News

The Mirasol pathogen reduction technology system (PRT) system is a proprietary technology that uses riboflavin and UV light to reduce the levels of infectious pathogens and inactivate white

The company believes that it can address the issues raised by the FDA in its complete response letter in a timely manner without conducting any additional clinical trials

The primary objective of the Phase I dose escalation study is to determine the safety, maximum tolerated dose and objective response rate of GRN163L when administered intravenously in

VX-770, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, was well-tolerated when dosed orally as 150mg or 250mg twice daily for 28 days. In this analysis, no

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, the company believes that RDEA806

Mr Clyde replaces Mark Casner, who resigned as president, CEO and director of the company to pursue new business opportunities. Mr Clyde has been CFO since November 2002

Following the recommendation for regulatory approval under the European decentralized procedure, Toctino has received national regulatory approval in France. Basilea will submit a pricing and reimbursement dossier to

The acquisition will be financed from the group’s financial resources. Novartis will acquire research, development and manufacturing assets of Nektar’s pulmonary business unit, including tangible assets as well

S Bio will utilize the proceeds to primarily fund the development efforts of its two lead compounds, SB939, a HDAC inhibitor, and SB1518, a JAK 2 inhibitor, both